Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) recommended new and strict guidelines which stated that researchers should proceed with extreme care and caution while testing pioneering drugs.
One such drug trial conducted on March left six volunteers in the state of coma. TGN1412, designed to treat leukemia, autoimmune and inflammatory diseases. The new drug was tested at the Parexel trial facility in Northwick Park Hospital caused organ failure and damaged the immune system of the volunteers.
Advertisement
The victims were given doses of the drug in turn, but by the time doctors realized its effect, all patients had been given the drug. Hence ABPI initiated a report which was mainly to make sure that such incidents do not repeat. A spokesman for the ABPI said that new guidelines are being recommended to the parliament for testing new drugs. German drug maker TeGenero AG, which produced TGN1412, filed for bankruptcy protection earlier this month.
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
The FDA advises consumers not to use compounded medications as an alternative to known diabetic and weight reduction medications Ozempic, Rybelsus, and Wegovy.
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.